Clever Leaves Holdings Inc (CLVR)

$3.8723

-0.06

(-1.47%)▲

Live

Insights on Clever Leaves Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 3.82M → 4.63M (in $), with an average increase of 8.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -5.13M → -2.22M (in $), with an average increase of 64.9% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 35.8% return, outperforming this stock by 93.5%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 43.7% return, outperforming this stock by 142.5%

Performance

  • $3.85
    $3.87
    $3.87
    downward going graph

    0.52%

    Downside

    Day's Volatility :0.58%

    Upside

    0.06%

    downward going graph
  • $1.72
    $9.60
    $3.87
    downward going graph

    55.56%

    Downside

    52 Weeks Volatility :82.08%

    Upside

    59.69%

    downward going graph

Returns

PeriodClever Leaves Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
50.58%
1.7%
0.0%
6 Months
62.4%
11.3%
0.0%
1 Year
-57.74%
5.4%
1.3%
3 Years
-98.75%
13.9%
-22.1%

Highlights

Market Capitalization
6.8M
Book Value
$14.02
Earnings Per Share (EPS)
-12.63
Wall Street Target Price
24.0
Profit Margin
-102.77%
Operating Margin TTM
-105.91%
Return On Assets TTM
-23.39%
Return On Equity TTM
-61.27%
Revenue TTM
17.4M
Revenue Per Share TTM
11.11
Quarterly Revenue Growth YOY
5.4%
Gross Profit TTM
6.8M
EBITDA
-13.2M
Diluted Eps TTM
-12.63
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Clever Leaves Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 519.79%

Current $3.87
Target $24.00

Company Financials

FY19Y/Y Change
Revenue
7.8M
-
Net Income
-48.1M
-
Net Profit Margin
-614.37%
-
FY20Y/Y Change
Revenue
12.1M
↑ 54.67%
Net Income
-41.4M
↓ 13.95%
Net Profit Margin
-341.78%
↑ 272.59%
FY21Y/Y Change
Revenue
15.4M
↑ 26.88%
Net Income
-45.6M
↑ 10.18%
Net Profit Margin
-296.81%
↑ 44.97%
FY22Y/Y Change
Revenue
17.8M
↑ 15.78%
Net Income
-66.1M
↑ 44.86%
Net Profit Margin
-371.35%
↓ 74.54%
FY23Y/Y Change
Revenue
17.4M
↓ 2.15%
Net Income
-15.0M
↓ 77.25%
Net Profit Margin
-86.34%
↑ 285.01%
Q4 FY22Q/Q Change
Revenue
4.6M
↑ 39.61%
Net Income
-28.8M
↑ 42.92%
Net Profit Margin
-624.53%
↓ 14.45%
Q1 FY23Q/Q Change
Revenue
4.0M
↓ 13.78%
Net Income
-4.1M
↓ 85.84%
Net Profit Margin
-102.59%
↑ 521.94%
Q2 FY23Q/Q Change
Revenue
5.0M
↑ 25.21%
Net Income
-3.6M
↓ 11.91%
Net Profit Margin
-72.17%
↑ 30.42%
Q3 FY23Q/Q Change
Revenue
3.8M
↓ 23.31%
Net Income
-5.1M
↑ 42.92%
Net Profit Margin
-134.5%
↓ 62.33%
Q4 FY23Q/Q Change
Revenue
4.6M
↑ 21.41%
Net Income
-5.1M
↓ 1.03%
Net Profit Margin
-109.64%
↑ 24.86%
Q1 FY24Q/Q Change
Revenue
4.6M
↑ 0.0%
Net Income
-2.2M
↓ 56.28%
Net Profit Margin
-47.93%
↑ 61.71%
FY19Y/Y Change
Total Assets
95.7M
-
Total Liabilities
45.5M
-
FY20Y/Y Change
Total Assets
165.9M
↑ 73.3%
Total Liabilities
51.6M
↑ 13.27%
FY21Y/Y Change
Total Assets
116.2M
↓ 29.97%
Total Liabilities
43.4M
↓ 15.86%
FY22Y/Y Change
Total Assets
52.1M
↓ 55.15%
Total Liabilities
11.7M
↓ 73.06%
FY23Y/Y Change
Total Assets
31.2M
↓ 40.03%
Total Liabilities
7.0M
↓ 39.9%
Q4 FY22Q/Q Change
Total Assets
52.1M
↓ 36.01%
Total Liabilities
11.7M
↓ 1.88%
Q1 FY23Q/Q Change
Total Assets
46.2M
↓ 11.25%
Total Liabilities
9.5M
↓ 19.02%
Q2 FY23Q/Q Change
Total Assets
42.8M
↓ 7.36%
Total Liabilities
8.9M
↓ 6.16%
Q3 FY23Q/Q Change
Total Assets
37.8M
↓ 11.8%
Total Liabilities
8.1M
↓ 8.95%
Q4 FY23Q/Q Change
Total Assets
31.2M
↓ 17.3%
Total Liabilities
7.0M
↓ 13.13%
Q1 FY24Q/Q Change
Total Assets
31.2M
↑ 0.0%
Total Liabilities
7.0M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-4.3M
-
Investing Cash Flow
-8.3M
-
Financing Cash Flow
27.5M
-
FY19Y/Y Change
Operating Cash Flow
-37.1M
↑ 766.51%
Investing Cash Flow
-33.9M
↑ 309.38%
Financing Cash Flow
62.8M
↑ 128.45%
FY20Y/Y Change
Operating Cash Flow
-22.0M
↓ 40.73%
Investing Cash Flow
-3.7M
↓ 89.19%
Financing Cash Flow
91.8M
↑ 46.16%
FY21Y/Y Change
Operating Cash Flow
-36.2M
↑ 64.99%
Investing Cash Flow
-7.3M
↑ 98.64%
Financing Cash Flow
1.8M
↓ 98.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-5.1M
↓ 5.35%
Investing Cash Flow
-44.0K
↓ 82.75%
Financing Cash Flow
-250.0K
↓ 106.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-6.1M
↑ 19.23%
Investing Cash Flow
-44.0K
↑ 0.0%
Financing Cash Flow
-107.0K
↓ 57.2%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.7M
↓ 72.24%
Investing Cash Flow
-44.0K
↑ 0.0%
Financing Cash Flow
165.0K
↓ 254.21%

Technicals Summary

Sell

Neutral

Buy

Clever Leaves Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Clever Leaves Holdings Inc
Clever Leaves Holdings Inc
-11.88%
62.4%
-57.74%
-98.75%
-98.99%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-0.91%
28.4%
35.75%
40.71%
78.24%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.95%
1.58%
-4.79%
12.69%
12.69%
Zoetis Inc.
Zoetis Inc.
-10.09%
-7.81%
-12.8%
-11.14%
48.17%
Viatris Inc.
Viatris Inc.
-2.37%
28.76%
25.82%
-14.76%
-29.31%
Catalent, Inc.
Catalent, Inc.
-0.8%
41.9%
32.08%
-51.64%
25.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Clever Leaves Holdings Inc
Clever Leaves Holdings Inc
NA
NA
NA
0.0
-0.61
-0.23
NA
14.02
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.72
56.72
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
30.04
30.04
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
225.0
225.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Clever Leaves Holdings Inc
Clever Leaves Holdings Inc
Sell
$6.8M
-98.99%
NA
-102.77%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
78.24%
56.72
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.4B
12.69%
30.04
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.17%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-29.31%
225.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
25.36%
211.02
-31.77%

Institutional Holdings

  • AdvisorShares Investments, LLC

    1.98%

  • Renaissance Technologies Corp

    1.97%

  • Vanguard Group Inc

    0.87%

  • Geode Capital Management, LLC

    0.61%

  • BlackRock Inc

    0.57%

  • Amundi

    0.48%

Corporate Announcements

  • Clever Leaves Holdings Inc Earnings

    Clever Leaves Holdings Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

clever leaves, a colombian company fully-licensed, will become the world’s largest grower with over 10mm+ ft2 of cultivation capacity by 2023, the largest extractor with pharmaceutical grade and gmp certified processing facilities, and the lowest cost operator in cannabis exports. one of the first colombian license holders in the medical cannabis industry. a company positioned to become a leader in the global market with a differentiated business model and strong positioning with regulators, physicians, and other relevant players. developing key capabilities to win in the new space of the medical cannabis industry with a highly experienced and respected team.

Organization
Clever Leaves Holdings Inc
Employees
296
CEO
Mr. Andres Fajardo
Industry
Healthcare

Discover More

FAQs